The high frequencies: their therapeutical effects
Are high frequencies really that effective?
Our devices are a technological and therapeutic innovation especially in the field of physical therapy and physiotherapy (Pronexibus Plus®) and in the field of difficult skin lesions (Rinovacell®). But why are they innovative? And who certified the results?
The innovation lies in the use of specific radio frequencies: the controlled high frequencies. Other types of radio frequencies are commonly used in the medical field: tecar-therapy, for example, uses lower frequencies – in the range of medium frequencies – which have a different biological behavior.
So the high frequencies are a complete innovation and a new alternative compared to electromedical devices already on the market, also can boast of the exceptional beneficial effects for the very short time in which they develop:
- Antalgic effect
- Anti-inflammatory effect
- Myorelaxant effect
- Anti-edema effect
- Proregenerative effect
But, who certified the results?
Therapeutical effects: painkiller ability and myorelaxation.
ProNexibus Plus®: Padova and Verona Universities.
Two independent studies have been developed thanks to the interest of the Universities of Padua and Verona.
The research group of the Prof. Masiero, through a protocol with 10 sessions of just 10-15 minutes each, found that the Pronexibus Plus® significantly reduces pain in the setting of several musculoskeletal problems (e.g. osteoarthritis of the knee, neck pain, tendinopathies of the shoulder and of the elbow); moreover they have highlighted that the patients have been facilitated in the resumption of both their work and social-related activities.
Independently, Dr Picelli’s research group used Pronexibus Plus® to relieve pain from muscle spasticity in patients who developed a stroke in the past. In this case the therapy was effective in reducing muscle spasticity even in the follow up.
Therapeutical effects: proregenerative, anti-edema and anti-inflammatory.
Rinovacell®: Salerno University – RITRALED study.
The Rinovacell® was studied at the University of Salerno, by the team of Dr Bruno Luigi Farina. The results were surprising: in patients with chronic diabetic foot ulcers, that is, skin lesions that have remained open for over 6 months, the treatment with Rinovacell® allowed the closure of the ulcer. Clinically, the researchers noted a very important reduction of the edema of the foot and a very important anti-inflammatory and antalgic effect: after 1 or 2 therapy sessions the patient’s foot was already deflated and no longer erythematous; after 10 sessions the ulcer has closed in almost all cases.
Safety and future directions.
In all the studies carried out with the devices FocusMed® there were no side effects, the therapy was well tolerated by the patients and, indeed, according to many researchers, many patients were impressed by the benefits that the therapy gave them.
The University of Verona, amazed by the experimental results obtained, wanted to continue research on our devices in the hope of finding new solutions to increasingly debilitating diseases.
The Rinovacell®, on the other hand, will be used in a double-blind research project in collaboration with the polyclinic of Abano to deepen the effects of the device in the context of diabetic foot pathology.
If you have come this far and want to learn more about how and why the beneficial effects develop on our body click here.
Masiero, S. et al. Short-wave diathermy in the clinical management of musculoskeletal disorders: a pilot observational study. Int. J. Biometeorol. (2019) doi:10.1007/s00484-019-01806-x.
ProNexibus Plus® for patients with spastc equinovarous foot lesion, University of Verona, Dr Picelli, 29-30th November 2019, 9° Congress I.S.Mu.L.T.
The RITRALED Study: Rinovacell in the treatmento of diabetic trophic lesions, University of Salerno, Dr Bruno Luigi Farina, 19th-21st September 2013, XII AIUC National Congress.